{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T06:11:51Z","timestamp":1775369511151,"version":"3.50.1"},"reference-count":74,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Digest Diseases"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Primary sclerosing cholangitis is a rare, complex autoimmune disease in relatively young patients. There is currently no treatment for the disease, resulting in high rates of advanced liver disease leading to death or liver transplantation. However, advances have been made in our understanding of the pathophysiological mechanisms of the disease, particularly from breakthroughs in the underlying genetics. Moreover, large international collaborations have generated important clinical data that have given greater detail on the different disease phenotypes and natural history, generating new risk prediction models. As a result, drug development may be designed to target specific disease mechanisms at known points of the disease natural history. Therefore, more drugs are entering phase II and III development, giving hope that soon patient\u2010specific treatments may be available to treat this difficult disease.<\/jats:p>","DOI":"10.1111\/1751-2980.12788","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T15:47:08Z","timestamp":1558108028000},"page":"346-356","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Precision medicine in primary sclerosing cholangitis"],"prefix":"10.1111","volume":"20","author":[{"given":"James B.","family":"Maurice","sequence":"first","affiliation":[{"name":"Department of Hepatology and Liver Transplantation Royal Free Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Liver Transplantation Royal Free Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.022"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3745"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.052"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.01.039"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26447"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316670"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000115"},{"key":"e_1_2_7_10_1","first-page":"1145","article-title":"The AESOP trial: a randomized, double\u2010blind, placebo\u2010controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis","volume":"66","author":"Kris V","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.038"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.07.005"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100406"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00872.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12979"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30093-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23082"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)64614-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.5.731"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.042"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04106.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.023"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.030"},{"key":"e_1_2_7_24_1","article-title":"Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis [published online ahead of print March 25, 2019]","author":"Rupp C","journal-title":"Gut"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255527"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-016-0847-z"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26620"},{"key":"e_1_2_7_28_1","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis [published online ahead of print March 15, 2019]","author":"Lemoinne S","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30276"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22938"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.12.009"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.02.013"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00772.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13402"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14806"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.030"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0265-7"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28256"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.11.048"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28963"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90673-9"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91449-E"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.4.610"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31872"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.4.562"},{"issue":"1","key":"e_1_2_7_46_1","first-page":"1864","article-title":"A novel prognostic model for transplant\u2010free survival in primary sclerosing cholangitis","volume":"67","author":"Vries EM","year":"2017","journal-title":"Gut."},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30766-2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30479"},{"key":"e_1_2_7_49_1","volume-title":"Reflection paper on regulatory requirements for the development of medicinal products for chronic non\u2010infectious liver diseases (PBC, PSC, NASH)","author":"European Medicines Agency","year":"2018"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110184"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315259"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5610"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1159\/000454904"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.009"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840"},{"key":"e_1_2_7_56_1","unstructured":"Intercept Pharmaceuticals. Intercept announces positive topline results from pivotal phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.http:\/\/ir.interceptpharma.com\/news\u2010releases\/news\u2010release\u2010details\/intercept\u2010announces\u2010positive\u2010topline\u2010results\u2010pivotal\u2010phase\u20103. Accessed March 29 2019."},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"e_1_2_7_58_1","first-page":"28A","article-title":"The non\u2010steroidal farnesoid X receptor (FXR) agonist GS\u20109674 improves liver biochemistry and decreases serum bile acids in patients with primary sclerosing cholangitis (PSC): a phase 2, randomized, placebo\u2010controlled trial","volume":"68","author":"Trauner M","year":"2018","journal-title":"Hepatology"},{"key":"e_1_2_7_59_1","unstructured":"US National Library of Medicine. Safety tolerability and efficacy of GS\u20109674 in non\u2010cirrhotic adults with primary sclerosing cholangitis (PSC\u2010phase 3).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03890120?term=GS-9674&rank=3. Accessed March 29 2019."},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818787400"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep39573"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.035"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.12.006"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311004"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14540"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14586"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12232"},{"issue":"4","key":"e_1_2_7_68_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo\u2010controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour S","year":"2016","journal-title":"J Gastrointest Liver Dis."},{"key":"e_1_2_7_69_1","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis\u2013ulcerative colitis [published online ahead of print August 21, 2018]","author":"Tan LZ","journal-title":"Gut."},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30237"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12639"},{"key":"e_1_2_7_72_1","unstructured":"British Society of Gastroenterology. NICE guidance on vedolizumab for treating moderately to severely active ulcerative colitis2015.https:\/\/www.bsg.org.uk\/resource\/nice\u2010guidance\u2010on\u2010vedolizumab\u2010for\u2010treating\u2010moderately\u2010to\u2010severely\u2010active\u2010ulcerative\u2010colitis.html. Accessed May 23 2019."},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14525"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14829"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2016.02.012"}],"container-title":["Journal of Digestive Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1751-2980.12788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-2980.12788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1751-2980.12788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1751-2980.12788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T01:12:54Z","timestamp":1694308374000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1751-2980.12788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/1751-2980.12788"],"URL":"https:\/\/doi.org\/10.1111\/1751-2980.12788","archive":["Portico"],"relation":{},"ISSN":["1751-2972","1751-2980"],"issn-type":[{"value":"1751-2972","type":"print"},{"value":"1751-2980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2019-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}